Clinical Trials Logo

Clinical Trial Summary

The goal of this project is to determine the efficacy of a treatment method that increase a participants sense of smell after suffering from COVID-19 related decline in smell. Participants have to be greater than 14 days from positive COVID-19 test and still have a decreased sense of smell. https://jaoa.org/article.aspx?articleid=2765119 this article is a review of literature regarding why OMT can have a positive effect on individuals suffering from COVID-19 Anosmia: Complete loss of smell Hyposmia: Decrease in smell


Clinical Trial Description

The goal of this project will be to determine if OMT can return the sense of smell to participants who previously contracted COVID-19. Participants will have to email a positive COVID-19 test result >14 days prior to [email protected] There will be a correspondence with the participant to ask them if they feel their sense is still decreased or absent and then candidacy for study will be determined. 20 participants will be divided randomly into sham OMT treatment groups and real OMT treatments. 10 in each group Participants will rate on a scale of 0-10 (0 being no smell, and 10 being pre-COVID19 exposure smell) the ability to smell the following items blindfolded pre-treatment as well as attempt to identify the substance: These will be performed with 1. Perfume 2. Red Onion (sliced) 3. Bourbon 4. Orange Participants in the sham treatment group will receive a non-osteopathic approach to treatment, which will consist of general palpation of head/neck/shoulder region. Participants in the Osteopathic Manipulation Therapy (OMT) group will receive: - Rib raising - Suboccipital Release - Thoracic Inlet Release - Miller Thoracic Pump - Pedal Pump - Cranial OMT, Performed Indirect Vault hold at conclusion Stevan Walkowski, D.O. will be providing treatment to both the OMT and Sham group. Participants will rate on a scale of 0-10 (0 being no smell, and 10 being pre-COVID19 exposure smell) to smell the following items blindfolded pre-treatment as well as attempt to identify the substance 10 min post-treatment: 1. Perfume 2. Red Onion (sliced) 3. Bourbon 4. Orange Participants will be debriefed following the research procedure. They will be informed of potential side effects that is listed in the risks or discomfort category and will be encouraged to drink water following treatment. Side effects from sham treatment group: Frustration of not re-acquiring sense of smell Side effects from OMT treatment group: Headache, dizziness, increase secretion (diarrhea, diuresis) from increase in fluid flow, frustration of not re-acquiring sense of smell Participants in both groups will be told of the side effects of the OMT treatment group and will be encouraged to drink water following treatment. Benefits from sham treatment group: none Benefits from OMT treatment group: May have an increase sense of smell post-treatment Multiple post-COVID19 individuals who lost sense of smell continue to have a decrease sense of smell after surviving the illness. These people have a decreased ability to smell food, drinks and enjoy shared human experiences which can lead to isolation. Individuals who have a decrease sense of smell are also in increased danger due to not being able to smell hazardous events around them i.e. smoke from a fire, gas filling their house from a leaking gas stove, spoiled food etc.. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05112887
Study type Interventional
Source Ohio University
Contact
Status Completed
Phase N/A
Start date March 31, 2021
Completion date September 13, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT04979858 - Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask N/A
Not yet recruiting NCT04999098 - Clinical Study to Assess the Antiviral Properties of Echinaforce Reducing Oropharyngeal Concentration and Infectivity of SARS-CoV2 Phase 4
Not yet recruiting NCT04978038 - Third Dose of COVID-19 Vaccine in LTCF Residents Phase 4
Active, not recruiting NCT05060510 - The School SPIT Study - COVID-19 Testing in Secondary Schools N/A
Active, not recruiting NCT05055505 - The School SPIT Study - Elementary Schools in Low COVID-19 Incidence Regions N/A
Active, not recruiting NCT05055492 - The School SPIT Study - Elementary Schools in High COVID-19 Incidence Regions N/A
Recruiting NCT05054218 - COVID-19 Immunogenicity of a Third Dose of mRNA-1273 Vaccine Among Cancer Patients
Recruiting NCT05076253 - Efficacy of Ivermectin in COVID-19 Phase 1/Phase 2
Not yet recruiting NCT05067946 - Evaluation of Efficacy, Safety and Immunogenicity of GX-19N in Healthy Individuals Who Have Received COVID-19 Vaccines Phase 2/Phase 3
Not yet recruiting NCT05030974 - RECOVAC Booster Vaccination Study Phase 4
Not yet recruiting NCT05077969 - Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients (Addendum 2) Phase 2
Not yet recruiting NCT05013034 - Exploratory Regimen of Basiliximab for Treatment of Pulmonary Cytokine Storm in SARS-CoV-2 Hospitalized Adult Patients Phase 2
Not yet recruiting NCT05094609 - Phase 1 Trial of ChAd68 and Ad5 Adenovirus COVID-19 Vaccines Delivered by Aerosol Phase 1
Not yet recruiting NCT05116657 - Obstructive Sleep Apnoea Post Covid 19: Role of the Upper Airway Microbiome
Not yet recruiting NCT05047783 - Masitinib in Patients With Symptomatic Mild to Moderate COVID-19 Phase 2
Not yet recruiting NCT04590222 - Impact of a Monoamine Oxidase Inhibitor on the Phenotype of Blood Mononucleated Cells in Patients With COVID-19
Active, not recruiting NCT04953039 - Use of Saliva for COVID-19 Diagnosis
Not yet recruiting NCT05122182 - Controlled Trial of Angiotensin Receptor Blocker (ARB) & Chemokine Receptor Type 2 (CCR2) Antagonist for the Treatment of COVID-19 Phase 2
Not yet recruiting NCT05074121 - NAC for Attenuation of COVID-19 Symptomatology Phase 2
Not yet recruiting NCT05089565 - Immune Response to SARS-CoV-2/COVID-19 Vaccination in Sarcoidosis